EDISON EQUITY RESEARCH - AMARIN
February 17 2015 - 9:03AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
AMARIN - VASCEPA COGS OILED UNTIL
REDUCE-IT REPORTS
Amarin has responded to a challenging year by focusing on cost
control measures and driving the sales launch of Vascepa with
copromotion partner Kowa, despite the headwind of generic entrants
in the >$1bn US Lovaza market. Initial sales data are
encouraging; investors will look for Amarin to manage costs and
increase Vascepa market share until the interim readout from the
REDUCE-IT Phase III trial, potentially in 2016.
Amarin has responded to a challenging year by focusing on cost
control measures and driving the sales launch of Vascepa with
copromotion partner Kowa, despite the headwind of generic entrants
in the >$1bn US Lovaza market. Initial sales data are
encouraging; investors will look for Amarin to manage costs and
increase Vascepa market share until the interim readout from the
REDUCE-IT Phase III trial, potentially in 2016.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024